Eli Lilly and Company $LLY Shares Sold by Candriam S.C.A.

Candriam S.C.A. reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.2% in the second quarter, HoldingsChannel.com reports. The firm owned 460,808 shares of the company’s stock after selling 20,046 shares during the period. Eli Lilly and Company comprises about 2.1% of Candriam S.C.A.’s investment portfolio, making the stock its 7th biggest holding. Candriam S.C.A.’s holdings in Eli Lilly and Company were worth $359,229,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth about $27,000. Blume Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares in the last quarter. IMG Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $35,000. TD Capital Management LLC lifted its stake in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares during the last quarter. Finally, IMA Advisory Services Inc. acquired a new stake in Eli Lilly and Company during the first quarter valued at approximately $55,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several research reports. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. UBS Group lifted their target price on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $981.89.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,018.28 on Thursday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market capitalization of $962.67 billion, a price-to-earnings ratio of 66.55, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a 50 day simple moving average of $815.33 and a 200-day simple moving average of $778.16. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,022.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.